A Phase 3, Randomized, Open-Label Study of Axatilimab Versus Best Available Therapy in Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy

Authors
Category Primary study
Registry of TrialsClinical Trials Information System
Year 2025
This article has no abstract
Epistemonikos ID: 1a6ae98fbecad5c68ac4507356923f6f5bd83bf5
First added on: Jan 17, 2026